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Commentary ʹ Tumor necrosis factor-ɲ antagonists as therapies for vitiligo  
 
Vitiligo is a common cutaneous disease resulting from the loss of epidermal melanocytes.
1
 
Although the aetiology and pathogenesis of vitiligo are not completely understood, 
cytotoxic T cell responses against melanocytes clearly play a prominent role in the 
pathophysiology of the disease.
2 
In addition, an imbalance of cytokines within vitiligo-
affected skin has been implicated in the destruction of melanocytes.
3
 For example, 
epidermal levels of the proinflammatory cytokine tumor necrosis factor (TNF)-ɲ are 
increased in vitiligo skin and, indeed, correlate directly with on-going depigmentation.
4
 TNF-
ɲcan activate cytotoxic T cells in the skin,5 inhibit the proliferation of melanocytes6 and also 
cause melanocytes to apoptose.
7
 Such findings have prompted the investigation of TNF-ɲ 
inhibitors as agents that may prevent melanocyte loss and also initiate repigmentation in 
vitiligo patients.  
 
In this issue of the BJD, Webb et al
8 
have reviewed the literature pertaining to the use of 
anti-TNF-ɲ mediators such as infliximab, etanercept and adalimumab as therapeutic tools 
for vitiligo. Their findings revealed that blocking the action of TNF-ɲĞĨĨĞĐƚŝǀĞůy stopped the 
progression of vitiligo and initiated repigmentation in almost all patients with active disease, 
presumably at least in part due to the stemming of cytotoxic T cell-mediated destruction of 
melanocytes. Importantly, the researchers noted that the arrest of melanocyte loss was as 
valid in assessing the success of treatment as observing actual repigmentation, concluding 
that future clinical trials will need to effectively evaluate both parameters. 
 
2 
 
Interestingly, the literature reported a small proportion of non-vitiligo patients who were 
receiving treatment with TNF-ɲ antagonists adalimumab and infliximab for other 
autoimmune diseases and who developed depigmentation. The authors of the review 
suggest that this phenomenon results from a decrease in the production and activation of 
regulatory T cells (Tregs) which are normally stimulated by TNF-ɲ9 and act to supress 
cytotoxic T cell activity.
10
 If Treg cell numbers are reduced in the skin, then T lymphocytes 
cytotoxic to melanocytes may exert their effects leading to pigment cell loss. Simultaneous 
treatment to recruit Tregs to the epidermis may overcome this adversity in susceptible 
individuals. 
 
Overall, inhibitors of TNF-ɲ were found to be beneficial for patients with progressing vitiligo. 
However, the possibility that vitiligo can be initiated by TNF-ɲ antagonists may thwart their 
wider use as treatments for the disease. 
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